RSV: A New Era in Prevention

An FDA decision on the company’s mRNA-1345 is slated for May 12.

The RSV prefusion F protein–based maternal vaccine phase 3 trial was halted due to the risk of this adverse event.

Impact of the RSVPreF3 vaccine on respiratory illness in older adults in the US.

A new strategy for universal infant immunization in the 2023-2024 RSV season faces implementation and medication access barriers.

High efficacy of Nirsevimab in preventing RSV hospitalizations was revealed.

Though a small number of infants received nirsevimab in the analysis, results support existing nirsevimab recommendations to prevent serious RSV disease in infants.

A new study shows that, among the tridemic viruses, RSV was the leading cause of pediatric hospitalizations.

Changes encompass clarification of recommendations for scheduled vaccinations and the addition of the RSV vaccines for the first time.

The panel discusses the importance of discussing the immunizations with patients now, as well as the value of them in future seasons.

In the third installment of RSV Roundtable, our panel discusses the impact nirsevimab has had this RSV season.

In the second installment of the RSV Roundtable, our panel explains how they are educating patients and parents when it comes to RSV, vaccines and preventive measures, and limited treatment availability.

Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.

A clinician discusses the vaccines' efficacy, which risk factors may rank higher for disease severity, and offers insights on counseling patients.

The FDA and CDC announced the availability of additional doses of nirsevimab-alip for infants at high-risk of infection.

Two RSV vaccines for seniors were FDA approved this year and here is an overview of the vaccines and the study data.

Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the benefits of having new tools to fight RSV in infants, potential vaccine hesitancy, and RSV trends currently being observed.

The federal agency says the data shows immunization reduces hospitalizations by more than 57 percent in first 6 months after birth.

The federal agency says infants of a certain age should receive this monoclonal antibody to protect against the virus.

Due to increased RSV activity in the southeast United States, the CDC has issued an official Health Alert Network Health Advisory. The federal agency recommends clinicians prepare to implement recently FDA-approved prevention methods.

From a virus that had no treatment options, to one that may be prevented in two different modalities, clinicians are hoping to see a reduction in respiratory syncytial virus (RSV) incidence rates, starting this fall.

The vaccine is intended to help prevent lower respiratory tract disease caused by respiratory syncytial virus in infants from birth to 6 months of age.

With the FDA approval of nirsevimab-alip (Beyfortus), which is indicated for prevention of respiratory syncytial virus (RSV) in infants, clinicians will need to have important conversations with families around this monoclonal antibody, beginning this fall.

A clinician offers a glimpse of what it is like to treat infants with respiratory syncytial virus (RSV). And with the recent FDA approval of nirsevimab, how that will likely benefit families and the youngest population.